Last reviewed · How we verify
Amphetamine Extended Release Suspension [Dyanavel] — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Amphetamine Extended Release Suspension [Dyanavel] (Amphetamine Extended Release Suspension [Dyanavel]) — Tris Pharma, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Amphetamine Extended Release Suspension [Dyanavel] TARGET | Amphetamine Extended Release Suspension [Dyanavel] | Tris Pharma, Inc. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Amphetamine Extended Release Suspension [Dyanavel] CI watch — RSS
- Amphetamine Extended Release Suspension [Dyanavel] CI watch — Atom
- Amphetamine Extended Release Suspension [Dyanavel] CI watch — JSON
- Amphetamine Extended Release Suspension [Dyanavel] alone — RSS
Cite this brief
Drug Landscape (2026). Amphetamine Extended Release Suspension [Dyanavel] — Competitive Intelligence Brief. https://druglandscape.com/ci/amphetamine-extended-release-suspension-dyanavel. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab